Compared to the controls, MDA was significantly improved in the asthma group, which was inhibited by the introduction of YFP (Figure 3(a)), while the decreased production of GSH-PX, SOD, and CAT in the asthma group was significantly elevated by the treatment of YFP (Figures 3(b)–3(d)). This evidence concerns the gene SOD1 and asthma.